Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Dec;16(12):777-792.
doi: 10.1111/crj.13552. Epub 2022 Oct 18.

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID-19: A systematic review and meta-analysis of cohort studies

Maryam Afraie  1 , Pardis Mohammadzedeh  1 , Mobin Azami  2 , Sorour Khateri  3 , Kamran Zamani  2 , Farhad Moradpour  4 , Yousef Moradi  4
Affiliations
Meta-Analysis

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID-19: A systematic review and meta-analysis of cohort studies

Maryam Afraie et al. Clin Respir J. 2022 Dec.

Abstract

Introduction: The aim of this review was to combine the results of published cohort studies to determine the exact association between chronic liver disorders, and the severe form of COVID-19, and its associated complications.

Methods: This meta-analysis employed a keyword search (COVID-19 and chronic liver disorders) using PubMed (Medline), Scopus, Web of Sciences, and Embase (Elsevier). All articles related from January 2019 to May 2022 were reviewed. The STATA software was used for analysis.

Results: The risk of death in COVID-19 patients with chronic liver disorders was higher than in ones without the chronic liver disease (RR: 1.52; CI 95%: 1.46-1.57; I2 : 86.14%). Also, the risk of acute respiratory distress syndrome (ARDS) and hospitalization in COVID-19 patients with chronic liver disorders was higher than in ones without the chronic liver disease ([RR: 1.65; CI 95%: 1.09-2.50; I2 : 0.00%] and [RR: 1.39; CI 95%: 1.23-1.58; I2 : 0.20%]). Also, the meta-analysis showed cough, headache, myalgia, nausea, diarrhea, and fatigue were 1.37 (CI 95%: 1.20-1.55), 1.23 (CI 95%: 1.09-1.38), 1.25 (CI 95%: 1.04-1.50), 1.19 (CI 95%: 1.02-1.40), 1.89 (CI 95%: 1.30-2.75), 1.49 (CI 95%: 1.07-2.09), and 1.14 (CI 95%: 0.98-1.33), respectively, whereas the risk of all these symptoms was higher in COVID-19 patients with chronic liver diseases than ones without chronic liver disorders.

Conclusion: The mortality and complications due to COVID-19 were significantly different between patients with the chronic liver disease and the general population.

Keywords: COVID-19; chronic liver disease; complications; meta-analysis; mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
The flowchart of search strategy and syntax
FIGURE 2
FIGURE 2
The pooled effect (risk ratio, RR) of chronic liver disorders on the mortality and admission to ICU related to COVID‐19
FIGURE 3
FIGURE 3
The pooled effect (risk ratio, RR) of chronic liver disorders on the ventilation needs, fever, and cough related to COVID‐19
See this image and copyright information in PMC

References

    1. Sharma A, Nagalli S. Chronic Liver Disease. StatPearls. StatPearls Publishing Copyright © 2022. StatPearls Publishing LLC; 2022.
    1. Sivakrishnan S, Pharm M. Liver disease overview. World J Pharm Pharm Sci. 2019;8(1):1385‐1395.
    1. Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol. 2021;22(9):608‐624. doi:10.1038/s41580-021-00373-7 - DOI - PubMed
    1. Wang X, Lin S‐X, Tao J, et al. Study of liver cirrhosis over ten consecutive years in southern China. World J Gastroenterol: WJG. 2014;20(37):13546‐13555. doi:10.3748/wjg.v20.i37.13546 - DOI - PMC - PubMed
    1. Matsuda M, Seki E. The liver fibrosis niche: novel insights into the interplay between fibrosis‐composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix. Food Chem Toxicol. 2020;143:111556. doi:10.1016/j.fct.2020.111556 - DOI - PMC - PubMed